A Product, News and Clinical Update
for the Electrophysiology Professional
August 8, 2008

Commonly Searched EP Topics


Left Atrial and Right Ventricular Pacing as a Treatment for Symptomatic Congestive Heart Failure
Features:
Left Atrial and Right Ventricular Pacing as a Treatment for Symptomatic Congestive Heart Failure

- Kourosh Moazemi, MD and Abraham G. Kocheril, MD Carle Heart Center and University of Illinois COM at Urbana-Champaign, Urbana, Illinois

In this article, the authors have provided a case report on treating congestive heart failure with left atrial and right ventricular pacing.


       Despite significant advances in medical therapy of congestive heart failure (CHF), patients with class III and IV CHF suffer from a poor quality of life and a grave prognosis.1,2
       Currently, there is ample evidence that atrial synchronized sequential pacing in left or both ventricles improves some electrical abnormalities and provides symptomatic relief for selected patients with stage III or IV CHF.3–7 Left atrial (LA) pacing remains unexplored as a treatment modality in these patients.

Figure 1.
ECG showing LA and RV pacing.


       Case Report. A 72-year-old man with stage III CHF due to ischemic cardiomyopathy and past medical history of myocardial infarction, hypertension, hypercholesterolemia, atrial fibrillation, and pacemaker for complete heart block, was admitted to have an upgrade from a VVIR to a biventricular pacemaker for further treatment of his persistent CHF symptoms (despite optimal medical therapy with lisinopril, digoxin, and carvedilol). He was found to have atypical atrial flutter on ECG and continuous monitoring (Figure 1).

Figure 2.
ECG prior to the procedure, showing the atypical flutter.


       During the procedure, multiple attempts to advance the lead intended for left ventricular pacing via the coronary sinus to a stable position failed. The lead was left in the coronary sinus, and was used to rapidly pace the left atrium to terminate atrial flutter and re-establish sinus rhythm. This lead was stable at the left atrial pacing site (Figure 2) and was attached along with the right ventricular lead to a dual chamber pacemaker. The lead was tested with excellent sensing and pacing parameters. Both two-week and two-month follow-up visits showed significant clinical improvement of CHF symptoms (to class II), exertion capacity, and quality of life. He continued to have appropriate left atrial and right ventricular pacing without evidence of atrial flutter or fibrillation (Figure 3).

Figure 3.
Chest X-ray.


       Conclusion. Biventricular pacing has become an accepted therapeutic modality in the treatment of symptomatic CHF, despite optimal medical therapy. In the event of failure of successful implantation of a lead at a LV site via the coronary sinus, a stable LA pacing site may be beneficial in advanced CHF. Especially in patients with atrial dysrhythmias, LA pacing may be as good an option as biventricular pacing for optimizing cardiac output and symptomatic relief. Some of the benefit may derive from left atrio-ventricular resynchronization. Further studies are needed to determine the appropriate candidates, as well as optimal LA pacing sites.


1. American Heart Association, Heart Disease and Stroke Statistics — Update. Dallas; American Heart Association; 2002.
2. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: Trends in case fatality in 66,457 patients hospitalized between 1986 and 1995. Circulation 2000;102:1126–1131.
3. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001;344:873–880.
4. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845–1853.
5. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA 2003;289:2685–2694.
6. Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003;42:1454–1459.
7. Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002;39:2026–2033.

EP Lab Digest - ISSN: 1535-2226 - Volume 5 - Issue 2 (Feb 2005) - February 2005 - Pages: 1 - 12

About HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC, which also owns the North American Center for Continuing Medical Education (NACCME). NACCME provides a wide array of accredited CME offerings with industry thought leaders participating in roundtable meetings, webcasts, symposia, conferences, seminars, podcasts and satellite programs. Discover more about HMP’s products and services at www.hmpcommunications.com. ©2008 HMP Communications

©2008 HMP Communications
|
All Rights Reserved
83 General Warren Blvd, Suite 100
|
Malvern, PA 19355
Phone: 610-560-0500
|
Fax: 866-488-8273
NACCME.com is your one-stop source for continuing education. Browse through archived webcasts, journal articles, as well as upcoming live events and symposia at www.naccme.com/cardiology














Search Articles




Contact Us

  • Subscribe to EP Lab Digest
  • Article Submission
  • Advertise with Us
  • Become a Spotlight Interview
  • Email Discussion Group
  • Letter to the Editor
  • Subscribe to EP Lab Enews
EP-AF